Handelsavisen
prelaunch
Companies Healthcare TNPH.PK
TN
TNPH.PK OTC Pharmaceuticals

Tnph.Pk

$0,01
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
34,7 %
ROE
21,8 %
Net margin
29,5 %
Debt / equity
0,00
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

TNPH.PK operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products.

Business. TNPH.PK operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
21,8 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning TNPH.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to TNPH.PK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    TNPH.PK operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    TNPH.PK maintains a strong liquidity position, with a current ratio of 14.21, indicating a significant ability to cover short-term liabilities with its current assets. The company holds $8.226 million in cash and equivalents, while its total liabilities amount to $0.953 million, and it has no long-term debt. This liquidity profile supports operational flexibility and financial stability.

    In terms of profitability, TNPH.PK demonstrates a return on equity (ROE) of 21.77%, which is a strong indicator of efficient capital use and profitability relative to shareholders' equity. The company's net income of $3.142 million and operating income of $3.698 million reflect a healthy margin structure, although a direct comparison to industry medians is not available in the provided data.

    TNPH.PK's revenue is not segmented by product or geographic region in the available data, so the extent of revenue concentration or diversification cannot be determined from the provided information. However, the absence of disclosed geographic or segment breakdowns suggests a potentially concentrated revenue base, which could pose a risk if market conditions in a specific region or product line were to deteriorate.

    The company's growth trajectory is not explicitly outlined in the provided data, but its current financial performance suggests a stable and profitable operation. No specific growth projections or revenue deltas for the current or next fiscal year are available in the input data. The company's capital expenditure of -$7,000 indicates a minimal investment in physical assets, which may reflect a focus on operational efficiency or a mature business model with limited expansion needs.

    TNPH.PK presents a low risk of dilution, with no immediate filing-based liquidity or dilution flags detected. The company's shares outstanding remain unchanged at 800 million for both basic and diluted shares, indicating no recent or anticipated share issuance that would dilute existing shareholders. The absence of long-term debt and the strong liquidity position further reduce financial risk exposure.

    No recent events, such as filings or transcripts, are provided in the input data to indicate any material changes in the company's operations or strategic direction. The company appears to be operating in a stable financial environment with no disclosed near-term risks or significant developments.

    Key takeaways
    • TNPH.PK has a strong liquidity position with a current ratio of 14.21 and no long-term debt.
    • The company's return on equity of 21.77% indicates efficient use of capital and strong profitability.
    • TNPH.PK's financial structure is stable, with no immediate liquidity or dilution risks.
    • The absence of geographic or segment data suggests a potentially concentrated revenue base.
    • The company's capital expenditure is minimal, indicating a mature business model with limited expansion needs.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $0,01
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    $8.2M
    Current ratio
    14.2
    Debt / equity
    0.0
    ROA
    ROE
    21.8%
    Cash conversion
    82.0%
    CapEx / revenue
    -0.1%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin34,7 %Best in class
    Net Margin29,5 %Best in class
    ROE21,8 %Best in class
    Capex / Rev-0,1 %Above P75
    D/E0,00Above P75
    Cash Conv0,82Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • TNPH.PK Market data — financials · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    TNPH.PKCanonical
    OTC · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage